Anuh Pharma Limited has informed the Exchange regarding 'Adoption For Policy For Implementation Of NFRA Circular'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY2026 revenue of Rs. 771.66 crore, up 16.6% from Rs. 661.51 crore in FY2025. However, profit after tax declined 13.3% to Rs. 41.05 crore from Rs. 47.35 crore in the prior year. EBITDA margin compressed to 8.56% from 10.64% due to higher material costs and forex losses. The board recommended a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval at the AGM on August 12, 2026. Nine promoter group members holding 0.95% stake (totaling 9.5 lakh shares) have sought reclassification from Promoter to Public category. The company also adopted the NFRA circular implementation policy and updated its MOA and AOA. Bonus shares in 1:1 ratio were allotted in July 2025, doubling the share capital to Rs. 5,011.20 lakh.
Revenue growth was strong but margin compression and lower profitability are concerns. The dividend provides income support. Promoter reclassification requests could increase public float and reduce promoter group holding, potentially improving liquidity.